Algert Global LLC increased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 401.3% ...
Leerink Partners analyst Mani Foroohar has maintained their neutral stance on ALNY stock, giving a Hold rating on November 25.Don't Miss our ...
Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) yesterday and set a price target of ...
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) – Investment analysts at Zacks Research increased their FY2024 ...
Zacks.com on MSN21h
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra UseALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.
The FDA has accepted Alnylam’s supplemental New Drug Application for Amvuttra on the heels of BridgeBio’s Attruby nod, ...
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
Delving into the details, we found 5% of traders were bullish, while 84% showed bearish tendencies. Out of all the trades we spotted, 14 were puts, with a value of $931,387, and 5 were calls, valued ...
NICE' has said that Wainzua can be used as an alternative to Alnylam's Amvuttra (vutrisiran), which was recommended for NHS ...
The presumptive new CDC director, Dave Weldon, is a known vaccine safety skeptic. In contrast, the FDA choice — Johns Hopkins ...
On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...
He also held leadership roles at Tolerx and Alnylam. Tony serves on the boards of Etherna, Chimeron Bio, Helfie AI and Lift ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback